BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 27546465)

  • 21. The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.
    Sigurdardottir EE; Turesson I; Lund SH; Lindqvist EK; Mailankody S; Korde N; Björkholm M; Landgren O; Kristinsson SY
    JAMA Oncol; 2015 May; 1(2):168-74. PubMed ID: 26181017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overview of monoclonal gammopathies of undetermined significance.
    Vogt RF; Marti GE
    Br J Haematol; 2007 Dec; 139(5):687-9. PubMed ID: 18021082
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation.
    Naina HV; Harris S; Dispenzieri A; Cosio FG; Habermann TM; Stegall MD; Dean PG; Prieto M; Kyle RA; Rajkumar SV; Leung N
    Am J Nephrol; 2012; 35(4):365-71. PubMed ID: 22473253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics.
    Greenberg AJ; Rajkumar SV; Vachon CM
    Blood; 2012 Jun; 119(23):5359-66. PubMed ID: 22354002
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study.
    Chang SH; Luo S; O'Brian KK; Thomas TS; Colditz GA; Carlsson NP; Carson KR
    Lancet Haematol; 2015 Jan; 2(1):e30-6. PubMed ID: 26034780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clues to pathogenesis of Waldenström macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance provided by analysis of immunoglobulin heavy chain gene rearrangement and clustering of B-cell receptors.
    Varettoni M; Zibellini S; Capello D; Arcaini L; Rossi D; Pascutto C; Rattotti S; Mangiacavalli S; Pochintesta L; Gotti M; Gaidano G; Cazzola M
    Leuk Lymphoma; 2013 Nov; 54(11):2485-9. PubMed ID: 23442064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence of secondary malignancies among patients with Waldenström macroglobulinemia: An analysis of the SEER database.
    Castillo JJ; Olszewski AJ; Hunter ZR; Kanan S; Meid K; Treon SP
    Cancer; 2015 Jul; 121(13):2230-6. PubMed ID: 25757851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Health-related quality of life in Waldenstrom Macroglobulinemia and IgM-related disorders: A single institution experience.
    Frustaci AM; Nichelatti M; Deodato M; Zamprogna G; Minga P; Pioltelli ML; Cairoli R; Tedeschi A
    Hematol Oncol; 2020 Feb; 38(1):111-113. PubMed ID: 31852014
    [No Abstract]   [Full Text] [Related]  

  • 29. The clinical spectrum of IgM monoclonal gammopathy: A single center retrospective study of 377 patients.
    Cao XX; Meng Q; Mao YY; Su W; Zhen JF; Shen KN; Zhang CL; Huang XF; Duan MH; Zhang W; Zhu TN; Cai HC; Chen M; Zhou DB; Li J
    Leuk Res; 2016 Jul; 46():85-8. PubMed ID: 27232065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
    Kyle RA; Rajkumar SV
    Oncology (Williston Park); 2011 Jun; 25(7):578-86. PubMed ID: 21888255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS).
    Bird J; Behrens J; Westin J; Turesson I; Drayson M; Beetham R; D'Sa S; Soutar R; Waage A; Gulbrandsen N; Gregersen H; Low E;
    Br J Haematol; 2009 Oct; 147(1):22-42. PubMed ID: 19673884
    [No Abstract]   [Full Text] [Related]  

  • 32. Prevalence of monoclonal gammopathy of undetermined significance in Asia: a viewpoint from nagasaki atomic bomb survivors.
    Iwanaga M; Tomonaga M
    Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):18-20. PubMed ID: 24461807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Monoclonal gammopathy of undetermined significance and asymptomatic multiple myelom in the year 2014 ].
    Adam Z; Krejčí M; Pour L; Sevčíková E; Křivanová A; Rehák Z; Koukalová R; Cermáková Z; Vaníček J; Sevčíková S
    Vnitr Lek; 2014 Oct; 60(10):861-79. PubMed ID: 25382009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance.
    Varettoni M; Zibellini S; Defrancesco I; Ferretti VV; Rizzo E; Malcovati L; Gallì A; Porta MGD; Boveri E; Arcaini L; Candido C; Paulli M; Cazzola M
    Haematologica; 2017 Dec; 102(12):2077-2085. PubMed ID: 28983055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Epidemiology of monoclonal gammopathy in a general hospital and a university internal medicine department].
    Decaux O; Rodon P; Ruelland A; Estepa L; Leblay R; Grosbois B
    Rev Med Interne; 2007 Oct; 28(10):670-6. PubMed ID: 17566610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Monoclonal gammopathies of undetermined significance called "MGUS"].
    Clément F
    Schweiz Med Wochenschr; 1989 Jul; 119(27-28):970-8. PubMed ID: 2508215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Cesana C; Klersy C; Barbarano L; Nosari AM; Crugnola M; Pungolino E; Gargantini L; Granata S; Valentini M; Morra E
    J Clin Oncol; 2002 Mar; 20(6):1625-34. PubMed ID: 11896113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders.
    Varettoni M; Zibellini S; Boveri E; Klersy C; Candido C; Rattotti S; Ferretti VV; Defrancesco I; Mangiacavalli S; Nizzoli ME; Flospergher E; Zerbi C; Bergamini F; Benvenuti P; Brociner M; Merati G; Paulli M; Arcaini L
    Br J Haematol; 2019 Nov; 187(4):441-446. PubMed ID: 31276195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Czech Registry of Monoclonal Gammopathies - Technical Solution, Data Collection and Visualisation.
    Brozova L; Schwarz D; Snabl I; Kalina J; Pavlickova B; Komenda M; Jarkovský J; Němec P; Horinek D; Stefanikova Z; Pour L; Hájek R; Maisnar V
    Klin Onkol; 2017; 30(Supplementum2):43-50. PubMed ID: 28903570
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidemiology of Monoclonal Gammopathy of Undetermined Significance (MGUS): The experience from the specialized registry of hematologic malignancies of Basse-Normandie (France).
    Cabrera Q; Macro M; Hebert B; Cornet E; Collignon A; Troussard X
    Cancer Epidemiol; 2014 Aug; 38(4):354-6. PubMed ID: 24880205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.